Neurodegenerative disease companies develop therapeutics, diagnostics and research technologies for conditions involving the progressive loss of neurons and nervous system function. Their work aims to improve disease detection, slow progression and address the underlying biology of neurodegeneration.
This category includes companies working on:
Browse 101 UK neurodegenerative disease companies below.
AI-driven combinatorial analytics platform for chronic disease biology
PrecisionLife is a computational biology company applying AI-driven combinatorial analytics to complex chronic diseases. Its platform identifies causal biological mechanisms and…
Specialty biopharma covering oncology, neurology, and fertility
Merck Serono Limited is the UK commercial subsidiary of Merck KGaA's Healthcare division, a German science and technology company founded in 1668. The UK operation markets…
Probiotic contract manufacturer and Lab4 platform developer
Cultech is a Welsh contract developer and manufacturer of probiotic and nutritional supplement products, operating one of the world's most advanced probiotic manufacturing…
Gene therapy company targeting inherited and degenerative diseases
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company developing AAV-based gene therapies for inherited retinal diseases, neurodegenerative conditions, and…
Regenerative cell therapy for sensorineural hearing loss
Rinri Therapeutics is a clinical-stage biotech developing allogeneic regenerative cell therapies for sensorineural hearing loss, a condition affecting over 400 million people…
Small molecule drugs targeting astrocytes in neurodegenerative disease
AstronauTx is a clinical-stage UK biotech developing oral small molecule therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's approach targets…
RNA-based therapeutics targeting neurodegenerative disease mechanisms
Harness Therapeutics is a Cambridge-based biotech developing oligonucleotide therapeutics that exploit post-transcriptional regulation to achieve controlled upregulation of…
DUB inhibitor therapeutics targeting mitophagy and degenerative disease
Mission Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule inhibitors of deubiquitylating enzymes to treat diseases driven by…
Global biopharma focused on severe neurological and immunological diseases
UCB Pharma is the UK subsidiary of UCB S.A., a Belgian biopharmaceutical company focused on the discovery and development of treatments for severe neurological and immunological…
AI-powered computational platform for covalent drug discovery
Axiom Therapeutics is a UK biotech company developing a computational platform for covalent drug discovery. Its platform combines machine learning with molecular physics to…
Small molecule therapeutics targeting astrocytes in Parkinson's disease
Cellestial Health is a pre-clinical stage biotechnology company and University of Cambridge spinout developing small molecule therapeutics for Parkinson's disease and other…
Not-for-profit research organisation targeting intrinsically disordered proteins
Bind Research is the UK's first Focused Research Organisation, established to make intrinsically disordered proteins druggable targets for new medicines. The organisation…